Skip to main content

Table 1 Baseline characteristics of case patients with pneumonia and control patients

From: Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study

  

Controls

Cases

  

Variables

 

N

(%)

N

(%)

Crude OR

(95 % CI)

P

Sample size

 

10,726

(100.0)

2,686

(100.0)

   

Female

 

3,280

(30.6)

824

(30.7)

   

Age (y)

Mean (± SD)

67.1

(±10.0)

67.1

(±10.0)

   

CHADS2 score

 0

8,830

(82.3)

1,703

(63.4)

1.00

(Ref.)

 

 1–2

1,695

(15.8)

838

(31.2)

3.33

(2.99–3.71)

<0.001

  > 2

201

(1.9)

145

(5.4)

5.85

(5.03–6.79)

<0.001

Comorbidities, yes (Ref. = No)

 Diabetes mellitus

800

(7.5)

552

(20.6)

3.33

(2.94–3.76)

<0.001

 Hypertension

418

(3.9)

268

(10)

2.77

(2.36–3.26)

<0.001

 Congestive heart failure

800

(7.5)

570

(21.2)

3.43

(3.04–3.87)

<0.001

 Stroke

1,372

(12.8)

654

(24.3)

2.21

(1.98–2.45)

<0.001

 Asthma

133

(1.2)

74

(2.8)

2.28

(1.70–3.04)

<0.001

 COPD

246

(2.3)

196

(7.3)

3.43

(2.82–4.18)

<0.001

 Chronic kidney disease

118

(1.1)

108

(4)

3.76

(2.88–4.91)

<0.001

 Chronic liver disease

28

(0.3)

16

(0.6)

2.29

(1.23–4.22)

0.008

 Parkinson disease

20

(0.2)

8

(0.3)

1.60

(0.70–3.63)

0.260

 Dementia

49

(0.5)

24

(0.9)

1.96

(1.20–3.19)

0.007

Medication use, yes (Ref. = No)

 Antineoplastic drug

67

(0.6)

71

(2.6)

4.35

(3.10–6.10)

<0.001

 PPI

1,127

(10.5)

665

(24.8)

2.86

(2.56–3.19)

<0.001

 Steroid

1,756

(16.4)

736

(27.4)

1.96

(1.77–2.16)

<0.001

 ACEI/ARB

5,983

(55.8)

1,674

(62.3)

1.33

(1.21–1.45)

<0.001

 Antiviral drug

143

(1.3)

47

(1.7)

1.32

(0.95–1.84)

0.100

 Immunosuppressants

19

(0.2)

12

(0.4)

2.53

(1.22–5.20)

0.010

 Immuostimulants

7

(0.1)

8

(0.3)

5.01

(1.72–14.5)

0.003

 Nitrate

6,277

(58.5)

1,847

(68.8)

1.62

(1.47–1.78)

<0.001

 Antiplatelet

9,151

(85.3)

2,330

(86.7)

1.13

(0.99–1.28)

0.050

 Vaccine (influenza or pneumococcal)

2,551

(23.8)

631

(22.8)

0.94

(0.85–1.05)

0.280

  1. ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blockade, CHADS 2 congestive heart failure, hypertension, age > 75 years, diabetes, previous stroke, CI confidence interval, COPD chronic obstructive pulmonary disease, OR odds ratio, PPI proton pump inhibitor, Ref reference group, SD standard deviation